United Therapeutics Corp. Stock Price, News & Analysis

United Therapeutics Corporation (Nasdaq: UTHR) has announced the enrollment of the first patient in the phase 3 TETON 2 study, involving 396 adult patients with idiopathic pulmonary fibrosis (IPF). This 52-week registration study aims to assess the impact of Tyvaso on forced vital capacity (FVC), a key prognostic indicator for IPF. The TETON program further investigates the antifibrotic effects of inhaled treprostinil. IPF is characterized by progressive lung scarring, leading to severe respiratory complications.

United Therapeutics Corporation (NASDAQ: UTHR) released its third annual Corporate Responsibility Report, showcasing its commitment to environmental, social, and governance (ESG) priorities. Highlights include the company's inaugural public benefit report, which emphasizes efforts to develop novel therapies and technologies for organ transplant availability. The report aligns with frameworks like GRI, SASB, and TCFD, and links progress to UN Sustainable Development Goals. The company is recognized as the first publicly traded biotech organized as a public benefit corporation.

United Therapeutics (NASDAQ: UTHR) reported a favorable ruling from the U.S. District Court regarding the infringement of its patents related to treprostinil inhalation. The Court determined that Liquidia Technologies' Yutrepia would infringe the ’793 patent, and an injunction preventing FDA approval until May 14, 2027, is expected. However, the Court invalidated certain claims of the ’066 patent. United Therapeutics plans to evaluate options for appeal regarding the ’066 patent while they continue to defend their intellectual property.

United Therapeutics Corporation (NASDAQ: UTHR) announced it will present four posters and one oral presentation at the upcoming European Society of Cardiology Congress 2022 and European Respiratory Society International Congress 2022 in Barcelona, Spain, from August 26 to September 6, 2022. The presentations will focus on clinical studies for Tyvaso^® (treprostinil) Inhalation Solution and Orenitram^® (treprostinil) Extended-Release Tablets, including data on event-free survival from the INCREASE study for Tyvaso in pulmonary hypertension associated with interstitial lung disease.

United Therapeutics Corporation (Nasdaq: UTHR) reported a 5% year-over-year revenue increase in Q2 2022, totaling $466.9 million. Key growth drivers included a 31% rise in Tyvaso sales, alongside the approval and launch of Tyvaso DPI for pulmonary arterial hypertension. However, net income fell 33% to $116.0 million, and EPS decreased 34%. The company is focused on ongoing clinical trials, notably for Tyvaso in various conditions, with a goal of reaching 6,000 patients on Tyvaso by year-end.

United Therapeutics Corporation (NASDAQ: UTHR) announced it will release its second quarter 2022 financial results on August 3, 2022, prior to market opening. A public webcast will follow at 9:00 a.m. ET on the same day, accessible via their website. United Therapeutics operates as a public benefit corporation, focusing on innovative therapies for patients and organ transplant technologies while aiming for superior financial performance and environmentally sustainable practices. Forward-looking statements are included in the release, cautioning potential risks and uncertainties.

United Therapeutics and 3D Systems Corporation have unveiled the world's most complex 3D-printed object – a human lung scaffold – at the LIFE ITSELF Conference in San Diego. The scaffolds, demonstrating gas exchange in animal models, consist of 44 trillion voxels with extensive pulmonary structures and are expected to enter human clinical trials within five years. Additionally, current methods extend the viability of human donor lungs, enhancing transplant availability. This initiative aligns with United Therapeutics’ goal to create an unlimited supply of transplantable organs.

United Therapeutics Corporation (Nasdaq: UTHR) will have CFO James Edgemond present an overview of the company during a fireside chat at the Jefferies Healthcare Conference. The session is set for June 9, 2022, from 11:00 a.m. to 11:25 a.m. EDT, and will be accessible through a live webcast on the company's website. An archived version will be available for 90 days post-event. United Therapeutics focuses on developing therapies for pulmonary arterial hypertension and aims to create transplantable organs, holding a unique public benefit corporation status.

United Therapeutics Corporation announced FDA approval for Tyvaso DPI (treprostinil) inhalation powder, the first dry powder inhaler for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). This new formulation enhances patient convenience and administration of treprostinil therapy. Commercial launch activities are currently underway, with patient availability expected by June 2022. The product aims to improve the exercise capacity and quality of life for approximately 75,000 patients affected by these conditions in the U.S.